Effect of long-term angiotensin II type I receptor antagonism on peripheral and coronary vasomotion

Cardiovascular Drugs and Therapy

Volumn 18, Issue 3, 2004, Pages 197-202

  Preumont, Nicolas ^a   Unger, Philippe ^a   Goldman, Serge ^a   Berkenboom, Guy ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

brachial artery; candesartan; coronary circulation; coronary heart disease; endothelium; regional blood flow

Indexed keywords

CANDESARTAN;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; COLD PRESSOR TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HEART MUSCLE BLOOD FLOW; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BELGIUM; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BRACHIAL ARTERY; COLD; CORONARY ARTERIOSCLEROSIS; CORONARY STENOSIS; CORONARY VESSELS; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPEREMIA; INDIVIDUALITY; MALE; PATIENT SELECTION; PHARMACOLOGY, CLINICAL; POSITRON-EMISSION TOMOGRAPHY; REGIONAL BLOOD FLOW; TETRAZOLES; TIME FACTORS; ULTRASONOGRAPHY; VASODILATION; VASOMOTOR SYSTEM;

EID: 3142750486     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CARD.0000033640.17844.4b     Document Type: Article

References (23)

1. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-265.
2. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-66.
3. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993;91:1453-1458.
4. Berkenboom G, Langer I, Carpentier Y, Grosfils K, Fontaine J. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: A bradykinin-dependent mechanism. Hypertension 1997;30:371-376.
5. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.
6. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850.
7. Saino A, Pomidossi G, Perondi R, et al. Intracoronary angiotensin II potentiates coronary sympathetic vasoconstriction in humans. Circulation 1997;96:148-153.
8. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-22357.
9. Rajagopalan S, Brook R, Mehta RH, Supiano M, Pitt B. Effect of losartan in aging-related endothelial impairment. Am J Cardiol 2002;89:562-566.
10. Anderson EA, Mark AL. Flow-mediated and reflex changes in large peripheral artery tone in humans. Circulation 1989;79:93-100.
11. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
12. Campisi R, Czernin J, Schoder H, et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation 1998;98:119-125.
13. Preumont N, Lenaers A, Goldman S, et al. Coronary vasomotility and myocardial blood flow early after heart transplantation. Am J Cardiol 1996;78:550-554.
14. Grandin C, Wijns W, Melin JA, et al. Delineation of myocardial viability with PET. J Nucl Med 1995;36:1543-1552.
15. Vanoverschelde JL, Melin JA, Bol A, et al. Regional oxidative metabolism in patients after recovery from reperfused anterior myocardial infarction. Relation to regional blood flow and glucose uptake. Circulation 1992;85:9-21.
16. Bol A, Melin JA, Vanoverschelde JL, et al. Direct comparison of [13N] ammonia and [150]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres. Circulation 1993;87:512-525.
17. Di Carli M, Czernin J, Hoh CK, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation 1995;91:1944-1951.
18. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986;8:37-44.
19. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-1319.
20. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation 2001;103:799-805.
21. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.
22. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-954.
23. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.